ctDNA-Guided Immunotherapy: A New Era of Gastric Cancer Recurrence Prevention

9 Views
Published
Samuel Cytryn, MD, Memorial Sloan Kettering Cancer Center, highlights how new data—including the recent New England Journal of Medicine study on neoadjuvant dostarlimab—underscore the exceptional sensitivity of MSI-high gastric cancers to immune checkpoint blockade, prompting a potential shift in treatment paradigms.
Category
Oncology
Be the first to comment